{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'accountability of study materials will be conducted by a representative of the Sponsor. Once', \"accountability is completed, the Sponsor's representative will authorize the return of study\", 'medication (all used, partially used, and unused vials) to', '.', 'The completed', 'Drug Accountability and Drug Return/Destruction Record(s) will be returned to the CRO', \"manager. The Investigator's copy of the Drug Accountability and Drug Return/Destruction\", 'Record(s) must document accurately the return of all study drug supplies and be maintained by', 'the pharmacist or designee until the study is complete and the database is locked. Records will', 'also include disposition dates and quantities returned to the designated facility.', '9.4.6 Study Drug Administration and Timing of Dose for each Subject', '9.4.6.1 Description of Clinical Supplies', 'will supply study drug to clinical sites. Ancillary supplies for dosing will', 'be provided by the study site (i.e., infusion bags containing normal saline, infusion', 'administration sets, syringes, needles, alcohol swabs, gauze pads, bandages, and biohazard', 'containers for safe storage of used needles and syringes).', '9.4.6.2 Determination of Dose Volume', 'The volume of study drug to be administered will be determined by the electronic data capture', \"(EDC) system and will be based on the subject's weight. The first dose will be 10 mg/kg, and\", 'subsequent doses will be 20 mg/kg. Weight will be measured on Day 1 and Weeks 12 and 24', 'during the Treatment Period. The dose on Day 1 may be based on the weight determined at the', 'most recent clinic visit, provided the most recent visit was within the prior 3 weeks. The doses', 'on Week 3 through Week 9 will be based on the weight determined on Day 1. The weight used', 'in the Week 12 dose calculation can be the weight determined on Day 1 or the weight obtained at', 'Week 12. The weight obtained at Week 12 can be used to adjust the dose beginning at Week 12', 'or Week 15 through Week 21, as appropriate.', '9.4.6.3 Details Concerning Timing and Dose Administration', '9.4.6.3.1 Preparation and Administration of Teprotumumab', 'Teprotumumab will be prepared by the site pharmacist or designee in accordance with', 'institutional policy and local regulations. Each vial of teprotumumab will be reconstituted with', '10 mL of water for injection. The resulting solution will have an approximate concentration of', '50 mg/mL teprotumumab antibody. Reconstituted teprotumumab solution will be further diluted', 'in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration by the site pharmacist or', 'designee.', 'Doses up to 1800 mg will be administered in a total infusion volume of 100 mL, and those above', '1800 mg will be administered in a total infusion volume of 250 mL. To maintain a constant', 'volume in the infusion bags, a volume equal to the volume of teprotumumab to be placed into the', 'infusion bag will be first removed from the infusion bag using a sterile syringe and needle. The', \"appropriate volume of reconstituted drug product solution based on the subject's dose and body\", 'weight will be withdrawn and the teprotumumab drug product solution will be diluted with', 'normal saline (0.9% NaCl) in the infusion bag.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 77 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'The IV infusion is to be administered at room temperature (20\u00b0C to 24\u00b0C [68\u00b0F to 75\u00b0F]). The', 'diluted product should be used within 4 hours of preparation. However, if not used within', '4 hours, and if dilution has taken place under controlled and aseptic conditions, the infusion', 'solution can be stored for up to 24 hours at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F).', 'No incompatibilities have been observed with:', 'administration sets with product contact surface of polyethylene, polyvinyl chloride', '(PVC), or polyurethane', 'inline filters with product contact surface of polyether sulphone', 'IV bags (0.9% sodium chloride) with product contact surface of polyolefin or PVC.', 'In-line filters are not required, but if a hospital is routinely using them, in-line filters with a', '0.2 um pore size should be utilized.', 'Exposure of the solution to direct sunlight should be avoided.', 'All parenteral products should be visually inspected for particulates before administration.', 'Partially used vials should not be re-used.', 'The first and second IV infusions on Day 1 and Week 3 will be administered over approximately', '90 minutes (but not less than 80 minutes) for all subjects; subsequent infusions may be', 'administered over a shorter time period (approximately 60 minutes, but not less than 50 minutes)', 'in the absence of any infusion-associated events. All subjects will be monitored for AEs from the', 'start of infusion through 60 minutes after infusion completion for the first 3 doses; the', 'monitoring period for subsequent doses may be reduced to 30 minutes after infusion completion', 'for subjects who do not experience infusion-associated events.', '9.4.6.3.2 Dose Modifications, Interruptions, and Delays', 'Subjects will be monitored for immediate infusion-associated events (e.g., nausea, vomiting,', 'facial flushing, warmth, dyspnea, dizziness, hypertension, hypotension, pruritus) and delayed', 'infusion-associated events (e.g., rash). If immediate infusion-associated events are noted, the', 'infusion rate will be slowed or interrupted, symptomatic treatment (e.g., antipyretics,', 'antihistamines, beta-agonists, oxygen, IV fluid) will be administered, and vital signs', '(temperature, blood pressure, pulse, and respiratory rate) will be monitored every 5 minutes until', 'stable and then every 15 minutes for 2 additional determinations. The infusion may be restarted', 'upon complete resolution of symptoms; however, study drug dosing will be permanently', 'discontinued if the event is an anaphylactic reaction.', 'If delayed infusion-associated events are noted, subjects may continue dosing at the', \"Investigator's discretion; however, if a rash worsens following repeated dosing or other signs of\", 'serum sickness (e.g., delayed fever, myalgias, arthralgias) are present, study drug dosing will be', 'permanently discontinued.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 78 of 118']\n\n###\n\n", "completion": "END"}